Matthews International Files Definitive Proxy Statement and Sends Letter to Shareholders
The Matthews team, under the leadership of Joe Bartolacci, has delivered solid performance. Notably, in fiscal 2024 Matthews reported $1.8 billion in consolidated revenue and met its revised guidance ...
Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes
Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim ...
Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Substantial, Rapid and Sustained Statistically Significant Reductions of Key Biomarkers Achieved Across Doses, Including up ...